Analysts are intrested in these 5 stocks: ( (VST) ), ( (ARDX) ), ( (ZS) ), ( (LXRX) ) and ( (ANET) ). Here is a breakdown of their recent ratings and the rationale behind them.
Vistra Energy has caught the attention of analysts with differing opinions on its future prospects. Ross Fowler has upgraded Vistra to a ‘Buy’ with a price objective of $152, citing the company’s potential in baseload generation and retail growth, despite recent underperformance. Fowler believes regulatory clarity will soon boost datacenter deals, offering significant upside. On the other hand, Neal Du has initiated coverage with a ‘Hold’ rating and a target price of $120, expressing caution over its current valuation despite acknowledging Vistra’s strong market position and potential benefits from the US power revival.
Ardelyx is gaining traction with its products Ibsrela and Xphozah, leading Julian Harrison to initiate coverage with a ‘Buy’ rating and a price target of $14. Harrison highlights the lack of competition in the IBS-C and hyperphosphatemia markets as a key factor for Ardelyx’s growth potential. The company has shown strong product-driven profitability and is expected to continue its momentum, making it an attractive opportunity for investors.
Zscaler has been upgraded to ‘Buy’ by both Catharine Trebnick and Tal Liani, with price targets of $235 and $240 respectively. Trebnick points to Zscaler’s strong Q2 performance, driven by improved billings growth and new product traction, as reasons for optimism. Liani echoes this sentiment, noting the company’s improved upsell capabilities and strong order growth. Both analysts see Zscaler’s innovations in zero-trust security as a key driver for future success.
Lexicon Pharmaceuticals faces challenges, leading Roanna Ruiz to downgrade the stock to ‘Hold’ with a price target of $1. Ruiz highlights concerns over the efficacy and safety signals in the Phase 2b trial of pilavapadin, as well as the slowing launch of Inpefa in heart failure. The competitive landscape and uncertainty in securing a partner for pilavapadin add to the company’s uphill battle, making it a cautious investment.
Arista Networks has been upgraded to ‘Buy’ by David Vogt, who raises the price target to $115. Vogt is optimistic about Arista’s position in the AI infrastructure build-out, supported by strong data center capex investments from hyperscalers. Despite concerns over competition from white-box vendors, Vogt believes Arista’s robust software advantages and key financial metrics provide a favorable risk/reward scenario for investors.